{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-23-000054","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.469476+00:00","generated_at":"2026-06-08T07:18:41.587870+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immuneering Q3 net loss $0.43/share; Phase 2a for IMM-1-104 expanded to 5 arms","bullets":["Net loss $12.6M ($0.43/sh) vs $12.8M ($0.49/sh) in Q3 2022.","Cash $97.2M at Sept 30, 2023 ($105.5M at Dec 31, 2022); runway into 2025.","Phase 1 dose evaluation of IMM-1-104 ~2/3 enrolled; no DLTs; Phase 2 dose recommendation expected early 2024.","Phase 2a expanded to 5 arms: 3 monotherapy (PDAC, melanoma, NSCLC) and 2 combinations (mFOLFIRINOX, gem/nab-paclitaxel); first patient dosing early 2024.","IND for IMM-6-415 on track for Q4 2023; Phase 1/2a to include RAS and RAF mutant disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-23-000054","json":"https://secwatch.observer/filing/0001790340-23-000054.json","markdown":"https://secwatch.observer/filing/0001790340-23-000054.md","text":"https://secwatch.observer/filing/0001790340-23-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034023000054/0001790340-23-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034023000054/imrx-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:18:41.587870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"610931d606ffdc6275f76994ff85d8cea32c6de0","claim":"Immuneering Corp reported for the quarter ended September 30, 2023 results: net income $12.6 million, EPS $0.43 per share.","evidence_excerpt":"Net loss attributable to common stockholders was $12.6 million, or $0.43 per share, for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034023000054/0001790340-23-000054-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended September 30, 2023"},{"label":"Net income","value":"$12.6 million"},{"label":"EPS","value":"$0.43 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}